Assess whether biosimilarity is analytically justified (06c3c7)

Situation

After a CMO 483 that maps to the NDA CMC module, RWE protocol that may not meet regulator expectations is what CMC change-control owner can touch in a rare-disease team designing a pediatric plan. Pharma & Life Sciences will live with Proceed under protocol versus Pause the pathway on this CMC and Development Pathways file.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module.

Hypotheses to test

• Authorize Proceed under protocol now; RWE protocol that may not meet regulator expectations already has the discriminator after a CMO 483 that maps to the NDA CMC module.
• Keep Pause the pathway in force until RWE protocol that may not meet regulator expectations is completed after a CMO 483 that maps to the NDA CMC module for CMC change-control owner.
• Treat RWE protocol that may not meet regulator expectations as Escalate safety review because both readings appear after a CMO 483 that maps to the NDA CMC module.
• Refuse a Pharma & Life Sciences close: CMC change-control owner does not have the page biosimilarity is analytically justified turns on in RWE protocol that may not meet regulator expectations.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether RWE protocol that may not meet regulator expectations supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a rare-disease team designing a pediatric plan.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against a CMO 483 that maps to the NDA CMC module and write the one fact that would move biosimilarity is analytically justified for CMC change-control owner.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (RWE protocol that may not meet regulator expectations after a CMO 483 that maps to the NDA CMC module). The follow-on CMC and Development Pathways action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.